SEC Filing Summary: ChromaDex Corp. (8-K)
Business Context and Reporting Period
This Form 8-K Current Report, dated February 1, 2012, covers events occurring on January 31, 2012. The registrant is ChromaDex Corp., a Delaware corporation. The filing discloses the entry into material definitive agreements regarding two simultaneous capital raising transactions: a Registered Direct public offering and a Private Placement.
Key Financial Metrics and Transaction Details
The filing details two distinct equity offerings priced at $0.75 per share:
- Registered Direct Offering: Sale of 9,533,333 shares of Common Stock for gross proceeds of $7,150,000. Net proceeds are expected to be approximately $6.4 million after deducting underwriting discounts, commissions, and offering expenses. The placement agent, Aegis Capital Corp., will receive $500,500 in fees and warrants to purchase 300,000 shares.
- Private Placement: Sale of 4,933,333 shares of Common Stock to accredited investors (including management) for gross proceeds of $3,700,000. The placement agent will receive $259,000 in fees.
- Total Capital Raised: Combined gross proceeds of $10,850,000 from the issuance of 14,466,666 shares.
The filing does not provide historical revenue, profit, cash flow, margin, or debt metrics. The primary financial impact is the anticipated increase in liquidity through the net proceeds of the Registered Direct Offering.
Material Changes and Agreements
The material change is the execution of the Placement Agreement and Securities Purchase Agreements on January 31, 2012. Key terms include:
- Closing Date: The Registered Offering is expected to close on or about February 6, 2012.
- Lock-Up Provisions: The Company, its directors, officers, and certain significant stockholders have agreed not to sell or dispose of Common Stock until April 30, 2012, without the written consent of the Placement Agent.
- Registration Basis: The public offering is conducted pursuant to an effective shelf registration statement on Form S-3 (No. 333-176636).
Guidance, Risks, and Management Commentary
The filing includes standard forward-looking statements regarding plans and objectives, specifically noting the uncertainty of securing capital for general working purposes. Management has disclaimed any obligation to update these statements. The primary risk highlighted is the reliance on the successful closing of these offerings to secure working capital. No specific operational guidance or revenue outlook is provided in this document.
Investor Verification Checklist
- Verify the actual closing date of the Registered Offering (expected February 6, 2012) and confirmation of fund receipt.
- Review the final prospectus supplement and the Placement Agreement (Exhibit 10.1) for detailed terms and conditions.
- Confirm the extent of dilution resulting from the issuance of 14,466,666 new shares and the 300,000 warrant shares.
- Monitor compliance with the lock-up agreement expiring April 30, 2012, regarding insider sales.
- Check subsequent filings for the actual use of the approximately $6.4 million in net proceeds.